WANG Chaoyang 1,2,3 , WENG Hong 4,5,6 , LI Binghui 1,2,3 , REN Xuequn 1,2,3 , ZENG Xiantao 2,3,4,5,6
  • 1. Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng, 475000, P.R.China;
  • 2. Center for Evidence-Based Medicine, Huaihe Hospital of Henan University, Kaifeng, 475000, P.R.China;
  • 3. Center for Evidence-Based Medicine, Henan University, Kaifeng, 475000, P.R.China;
  • 4. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, 430071, P.R.China;
  • 5. Center for Evidence-Based and Translational Medicine, Wuhan University, Wuhan, 430071, P.R.China;
  • 6. Department of Evidence-Based Medicine and Clinical Epidemiology, The Second Clinical Medical College of Wuhan University, Wuhan, 430071, P.R.China;
REN Xuequn, Email: renxuequn001@163.com; ZENG Xiantao, Email: zengxiantao1128@163.com
RevMan software; Effect size; Confidence interval; Risk ratio; Hazard ratio; Odds ratio; Data transformation; Meta-analysis
10.7507/1672-2531.201704069
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Etiological and prognostic studies always directly reported effect size with its 95% confidence interval, hence, data transformation was needed when performing meta-analysis based on these studies. Using the data of risk ratio, hazard ratio, odds ratio and 95% confidence interval as an example, this paper introduces the process of using RevMan 5.3 software to convert data and perform meta-analysis.

Citation： WANG Chaoyang, WENG Hong, LI Binghui, REN Xuequn, ZENG Xiantao. Application of RevMan 5.3 software for data transformation in etiological and prognostic meta-analysis. Chinese Journal of Evidence-Based Medicine, 2017, 17(7): 852-856. doi: 10.7507/1672-2531.201704069 Copy

  • Previous Article

    Brief introduction of Bayesian N-of-1 trials

  • Next Article

    Introduction of Core Outcome Set-STAndards for Reporting (COS-STAR)